REVIEW article
Front. Oncol.
Sec. Cancer Molecular Targets and Therapeutics
Volume 15 - 2025 | doi: 10.3389/fonc.2025.1418537
This article is part of the Research TopicRAS Inhibitor Therapy of CancerView all 5 articles
MAPK -Targeted Therapies in Non-Gastro-Intestinal Stromal Tumors Soft Tissue Sarcoma: Current Landscape and Prospect
Provisionally accepted
- 1Department of Medical Oncology, Mohammed VI University Hospital, Oujda, Morocco
- 2Faculty of Medicine and Pharmacy, Mohamed Premier University, Oujda, Morocco
- 3Faculty of Medical Sciences, Mohammed VI Polytechnic University, Ben Guerir, Morocco
Select one of your emails
You have multiple emails registered with Frontiers:
Notify me on publication
Please enter your email address:
If you already have an account, please login
You don't have a Frontiers account ? You can register here
Non-Gastrointestinal Stromal Tumors (Non-GIST) Soft Tissue Sarcomas (STS) are highly aggressive and challenging diseases with poor prognosis and limited therapeutic options. Molecular profiling is urgently required to gain a deeper understanding of STS pathogenesis and to identify a comprehensive landscape of genomic alterations in order to develop effective targeted therapies. The mitogen-activated protein kinase (MAPK) signaling pathway is a key molecular mechanism involved in sarcoma development. This study aims to conduct a literature review on the involvement of the MAPK cascade in non-GIST STS, with a focus on the role of MAPK inhibitors in the current treatment paradigm for STS. Furthermore, recent data have provided promising preliminary findings regarding the use of new molecular agents targeting the MAPK pathway, either as single therapies or in combination with other drugs. Numerous clinical trials are currently ongoing, and their outcomes are eagerly awaited. Further research is required in both translational and clinical settings to molecularly characterize STS, identify novel causal alterations, accelerate target discovery, and identify potential biomarkers. Moreover, the development of novel nanomaterials provides a promising perspective that may lead to significant advancements in clinical practice.
Keywords: soft tissue sarcomas, MAPK pathway, targeted therapy, Personalized approach, clinical trials
Received: 16 Apr 2024; Accepted: 17 Jun 2025.
Copyright: © 2025 Al Jarroudi, El Bairi, Brahmi and afqir. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
* Correspondence: Ouissam Al Jarroudi, Department of Medical Oncology, Mohammed VI University Hospital, Oujda, Morocco
Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.